Arvinas, Inc.
↗New Haven, Connecticut, United States
Arvinas is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in New Haven, Connecticut. The company is pioneering the development of PROTAC (Proteolysis-Targeting Chimera) protein degraders—a revolutionary class of therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein disposal system. Built on groundbreaking research from Yale University founder Craig M. Crews, Ph.D., Arvinas has established itself as the leader in targeted protein degradation technology. The company's proprietary PROTAC Discovery Engine enables the targeting of previously "undruggable" intracellular disease targets representing up to 80% of all proteins. Arvinas is the first targeted protein degradation company with an investigational drug to complete a pivotal trial and submit an NDA to the FDA.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biopharmaceuticals
Sub-Industry:Protein Degradation Therapeutics
SIZE & FINANCIALS
Employees:201-500
Revenue:$40M-$80M
Founded:2013
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$300M+ (pre-IPO) + $123.2M IPO proceeds
Investors:Nextech Invest (Series C lead), Deerfield Management, Hillhouse Capital, Sirona Capital, Multiple IPO investors
STOCK
Exchange:NASDAQ
Ticker:ARVN
Market Cap:$785M-$858M
PIPELINE
Stage:Phase 1-3
Lead Drug Stage:Phase 3 (Vepdegestrant awaiting FDA decision)
Modalities:Small molecule PROTAC, Protein degraders, E3 ligase-based therapeutics
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 1 | Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., Arvinas Winchester, Inc.
Key Partnerships:Pfizer - Vepdegestrant co-development and co-commercialization (now seeking third-party partner), Novartis - ARV-766 (Luxdegalutamide) global development and commercialization license ($1.01B milestone deal, April 2024), Yale University - PROTAC technology platform licensing
COMPETITION
Position:Leader
Competitors:Kymera Therapeutics, Nurix, Amphista, Halda Therapeutics (acquired by Johnson & Johnson, 2025, $3B), Moderna, Jazz Pharmaceuticals, BeiGene
LEADERSHIP
Key Executives:
John Houston, Ph.D. - Chief Executive Officer, President, Chairman
Craig M. Crews, Ph.D. - Founder, Chief Scientific Advisor
Angela M. Cacace, Ph.D. - Chief Scientific Officer
Noah Berkowitz, M.D., Ph.D. - Chief Medical Officer
Andrew Saik - Chief Financial Officer, Treasurer
Jared Freedberg, J.D. - General Counsel, Corporate Secretary
Scientific Founders:Craig M. Crews, Ph.D. (Yale University)
Board Members:Timothy Shannon (Chairman), John Houston, Ph.D., Briggs Morrison, M.D., Sunil Agarwal, M.D., Laurie Smaldone Alsup, M.D., Linda Bain, Everett Cunningham, Ted Kennedy, Jr., J.D., Leslie Norwalk, Esq., Randy Teel, Ph.D.
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Arvinas, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Arvinas, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.